KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Notes Payables (2016 - 2024)

Emergent BioSolutions (EBS) has 8 years of Notes Payables data on record, last reported at $800000.0 in Q3 2024.

  • For Q3 2024, Notes Payables changed N/A year-over-year to $800000.0; the TTM value through Sep 2024 reached $800000.0, changed N/A, while the annual FY2023 figure was $413.7 million, 56.78% down from the prior year.
  • Notes Payables reached $800000.0 in Q3 2024 per EBS's latest filing, down from $415.2 million in the prior quarter.
  • Across five years, Notes Payables topped out at $957.3 million in Q4 2022 and bottomed at $800000.0 in Q3 2024.
  • Average Notes Payables over 5 years is $220.8 million, with a median of $31.6 million recorded in 2021.
  • Peak YoY movement for Notes Payables: soared 2929.43% in 2022, then crashed 56.78% in 2023.
  • A 5-year view of Notes Payables shows it stood at $33.8 million in 2020, then dropped by 6.51% to $31.6 million in 2021, then skyrocketed by 2929.43% to $957.3 million in 2022, then plummeted by 56.78% to $413.7 million in 2023, then plummeted by 99.81% to $800000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $800000.0 in Q3 2024, $415.2 million in Q2 2024, and $459.2 million in Q1 2024.